Concepedia

Kelly Bleasby

KB

19

Publications

1.1K

Citations

15

H-Index

2000

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Newcastle University

Merck Canada Inc. (Canada)

National Institute of Environmental Health Sciences

Kelly Bleasby is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and drug discovery.

Top concepts

Publications per year

2000–2023

19

Publications

19

Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition

Kelly Bleasby, John C. Castle, C. J. Roberts et al. · Xenobiotica · 2006 · 265 citations

, , +19

Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

Xiaoyan Chu, Kelly Bleasby, Jocelyn Yabut et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 175 citations

Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia

Renata M. Oballa, Liette Belair, W. Cameron Black et al. · Journal of Medicinal Chemistry · 2011 · 140 citations · Full text

, , +18

Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6)

Kelly Bleasby, Laura A. Hall, Jennifer L. Perry et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 120 citations

The organic cation transporter OCT2 mediates the uptake of <i>β</i>‐adrenoceptor antagonists across the apical membrane of renal LLC‐PK<sub>1</sub> cell monolayers

Adam J. Dudley, Kelly Bleasby, Colin Brown · British Journal of Pharmacology · 2000 · 74 citations · Full text

Rows per page

1–5 of 19